Social media

Join Luke Gregory at #ACDM26 as he explores why artificial intelligence is only one part of a truly effective clinical data science toolkit. Drawing on practical examples, he will show how thoughtful problem assessment, ...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Flow cytometry is rapidly evolving - driven by high parameter and spectral technologies, smarter data analytics and global standardisation efforts. This Spotlight hosted by Bioanalysis Zone brings together leading expe...

Today on Rare Disease Day, explore how ICON is supporting a global phase 3 clinical trial in Generalised Myasthenia Gravis (gMG), a rare autoimmune disorder affecting an estimated 700,000 people worldwide. By navigatin...

Approximately 5% of the world’s population is affected by a Rare Disease. ICON is committed to raising awareness and generating change for people worldwide living with Rare Diseases, their families and carers. Learn ho...

New qualitative research from ICON explores patient experiences in advanced/metastatic hepatocellular carcinoma, identifying fatigue, weight loss, weakness, appetite reduction, and sleep disturbance as the most frequent ...

New qualitative research from ICON explores patient experiences in advanced/metastatic hepatocellular carcinoma, identifying fatigue, weight loss, weakness, appetite reduction, and sleep disturbance as the most frequent ...

Come along to Rüdiger Kaspera's Learning Lab at ASCPT, where he’ll dive into science and risk based strategies for designing oligonucleotide First‑in‑Human studies - covering toxicity, study design, PK/PD, population se...

Ultra rare disease progress does not happen by accident. Register for our webinar to hear how patient leaders are accelerating therapies and redefining what is possible through practical, repeatable expert‑proven model...

Patient leadership is a catalyst for innovation in ultra rare diseases. Hear directly from leaders who are challenging regulatory norms, driving first in human treatments and bringing hope and treatments to families fast...

Rare Disease Day takes place on 28 February. ICON is committed to raising awareness for the 300 million people impacted globally. Over the past 5 years, ICON has participated in 810+ rare disease clinical studies, enro...

Heading to ADPD 2026? Visit ICON at booth \#29 to discuss how our early development and neuroscience teams support more informed decision making in neurodegenerative research. With in house early phase capabilities and...